Nesiritide (BNP) in the management of postoperative cardiac patients

被引：31

作者：

Moazami, N ^{[1
]}

Damiano, RJ ^{[1
]}

Bailey, MS ^{[1
]}

Hess, RL ^{[1
]}

Lawton, JS ^{[1
]}

Moon, MR ^{[1
]}

Pasque, MK ^{[1
]}

机构：

[1] Univ Washington, Sch Med, Div Cardiothorac Surg, St Louis, MO USA

来源：

ANNALS OF THORACIC SURGERY | 2003年 / 75卷 / 06期

关键词：

D O I：

10.1016/S0003-4975(02)05009-9

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Recombinant human B-type natriuretic peptide (BNP) is a promising new agent in the management of heart failure. The pharmacologic properties of BNP make it desirable to use in a subset of patients after cardiac surgical operations. Among these therapeutic potentials is the effect on markedly reducing pulmonary vascular resistance and central venous pressure with mild systemic vasodilatation. In addition, BNP directly effects the kidneys to promote natriuresis. We believe this agent to be useful in the treatment of the postcardiac surgery patients with left ventricular dysfunction and mild to moderate renal insufficiency. This report summarizes our experience in 2 patients. (C) 2003 by The Society of Thoracic Surgeons.

引用

页码：1974 / 1976

页数：3

共 5 条

[1] Effect of atrial natriuretic peptide on muscle sympathetic activity and its reflex control in human heart failure [J].